A 2.4-mg weekly injection of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide led to a clinically meaningful 5% loss in weight for roughly two thirds of patients with both overweight/obesity and type 2 diabetes, researchers report. These findings from the Semaglutide Treatment Effect in People With Obesity 2 (STEP 2) trial, one of four phase